Form 4: Eton Pharmaceuticals CFO James R. Gruber Reports Stock Option and Restricted Stock Unit Grants

James R. Gruber, CFO of Eton Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• On January 3, 2025, James R. Gruber, the Chief Financial Officer of Eton Pharmaceuticals, Inc., reported the acquisition of new securities.
• These include 38,621 employee stock options with an exercise price of $13.
• The options vest in 48 equal monthly installments from the grant date, becoming fully vested and exercisable on January 3, 2029.
• Gruber also acquired 25,876 restricted stock units (RSUs), each representing a contingent right to receive one share of ETON Common Stock.
• These RSUs vest in four equal annual installments starting January 3, 2026, contingent upon continued employment with the issuer.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the company's future.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Eton Pharmaceuticals' stock.
• The RSUs are contingent upon continued employment, meaning they could be forfeited if employment is terminated before vesting.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of future value creation.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the pharmaceutical industry.
• Vesting schedules, such as the monthly vesting for options and annual vesting for RSUs, are also typical.
• Comparing the size of the grants to those of peer companies would require further analysis of Eton Pharmaceuticals' compensation policies and executive pay data.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates